A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose
Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of
AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly
Volunteers and in Mild-to-Moderate Alzheimer Disease Patients

Inclusion Criteria:

- Part 1: Healthy elderly male and female (of non-childbearing potential) subjects.

- Part 2: Male and non-fertile female AD patients.

- Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more
than 100 kg.

- Part 2: Clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria.

- Part 2: Manifestation of AD symptoms at least 6 months before randomization.

Exclusion Criteria:

- Part 1: History or presence of psychiatric disease/condition, GI, renal, hepatic,
cardiovascular, psychiatric, or retinal diseases or disorders.

- Part 2: Significant disease affecting the CNS other than Alzheimer's disease,
including but not limited to other dementias, other significant neurological or major
psychiatric disease.

- History of use of antipsychotic drugs , or chronic use of antidepressant or
anxiolytic drugs.

- Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other
nicotine products.

- History of neurological disease, including seizures, recent memory impairment, or
clinically significant head injury.